SG/CALL/EDWARDS LIFESCIENCES/75/0.1/20.12.24 | Market Closed - Deutsche Boerse AG 01:12:36 29/06/2024 am IST | ||
| 2.05 EUR | -4.65% |
|
| Current month | +22.02% | ||
| 1 month | +16.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 2.05 | -4.65% |
| 27/24/27 | 2.15 | +7.50% |
| 26/24/26 | 2 | +3.09% |
| 25/24/25 | 1.94 | +1.04% |
| 24/24/24 | 1.92 | -1.03% |
Delayed Quote Deutsche Boerse AG
Last update June 29, 2024 at 01:12 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | 
Société Générale
|
| WKN | SU2MAN |
| ISIN | DE000SU2MAN7 |
| Date issued | 22/11/2023 |
| Strike | 75 $ |
| Maturity | 20/12/2024 (174 Days) |
| Parity | 10 : 1 |
| Emission price | 1.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.73 € |
|---|---|
| Lowest since issue | 1.02 € |
| Spread | 0.01 € |
| Spread % | 0.49% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
92.37
USD
Average target price
96.05
USD
Spread / Average Target
+3.99%
- Stock Market
- Warrants
- Warrant
